Durham, NC, October 30, 2015 – GeneCentric Diagnostics, Inc., a company devoted to changing the taxonomy of cancer through the analysis of tumor genomics, today announced that it will present new data on its lung cancer subtyping product, LSP™ 120, at the Association for Molecular Pathology (AMP) 2015 Annual Meeting being held November 5-7, 2015 at the Austin Convention Center in Austin, Texas. LSP™ 120 was developed using GeneCentric’s Cancer Subtyping Platform (CSP™), which provides precision medicine solutions for patient diagnosis and treatment, as well as advanced patient stratification in drug development and clinical trials.
Details of the presentation are as follows:
Title: “Lung Subtyping Signature for Predicting Survival in Lung Adenocarcinoma and Relationship to Other Gene Expression Prognostic Panels”
Poster Number: ST49
Date: Saturday, November 7
Time: 9:45 a.m. to 10:45 a.m. CT
Location: Austin Convention Center Exhibit Hall
Presenter: Hawazin Faruki, DrPH, Vice President for Clinical Development, GeneCentric
“The performance of LSP™ 120 compares favorably with other prognostic signatures in patients with lung adenocarcinoma, ,” said Dr. Faruki. “We are continuing to develop LSP™ 120 as a tool for the stratification of patients in clinical trials and improved therapeutic management in clinical settings.”
For more information on the AMP 2015 Annual Meeting – Realizing the Dream of Precision Medicine, visit: http://www.amp.org/meetings/2015/.
GeneCentric Diagnostics, Inc. is a company devoted to changing the taxonomy of cancer through an integrated analysis of tumor pathology and genomics. GeneCentric is redefining the advanced classification of cancers through the development and commercialization of its proprietary Cancer Subtype Platform (CSP™). By capturing a comprehensive picture of DNA, RNA and copy number biomarkers, CSP™ can better enable drug developers and oncologists to make more individualized treatment decisions and meet the growing demand for precision medicines. GeneCentric’s first application of CSP™ was launched with partner LabCorp® and is available as HistoPlusSM: Lung Cancer.
For more information, please visit www.genecentric.com.
Dr. Myla Lai-Goldman, CEO
GeneCentric Diagnostics, Inc.